-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $131

Benzinga·12/17/2025 19:54:57
Listen to the news
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $132 to $131.